Endoret® PRGF®
Endoret® (PRGF®) is a platelet-rich plasma (PRP) technology for obtaining autologous proteins from the patient’s own blood.
The fibrin-free plasma rich in growth factors formulation has been developed for daily use, is kept at ambient temperature and can be used anywhere and at any time.
Formulation
Endoret® PRGF® is a closed system, with the necessary equipment and unitary and disposable kits certified for such use that allows a rapid preparation of plasma under sterile conditions and its immediate application.
Why use Endoret instead of other PRPs?
The Endoret system provides many advantages:
> Autologous and rich in Growth Factors
- No adverse effects or incompatibility risks
- It promotes homeostasis
- Stimulates cell proliferation and migration
- It stimulates the endogenous secretion of proteins from the extracellular matrix
> Optimal concentration of Growth Factors
- Platelet concentration compared to baseline between 2 and 3 times
- Balance between growth factors:
- Platelet-based (released by platelets)
- Plasma-based (present free in plasma)
> Free from leukocytes and inflammatory proteins
- Reduces inflammation, pain, and tissue fibrosis
- Preserves the integrity of the fibrin matrix over time
> Controlled activation
- Promotes the release of growth factors from platelet
- Induces polymerisation of the fibrin matrix
> Dual effect and bioavailability
- Endoret PRGF works on tissues with its double action:
- Immediate, due to the effect of the growth factors at the time of application
- Prolonged over time, thanks to the fibrin matrix that acts as a reservoir for sustained release
> Versatility
- Makes it possible to prepare specific formulations adapted to each tissue and clinical need
> Security and compliance guarantees
- All necessary medical equipment and devices for Endoret closed system technology:
- They have CE marking for obtaining Plasma Rich in Growth Factors (PRGF)
- They comply with the most exhaustive quality controls in compliance with the current regulations (control of endotoxins and sterility, etc…)
- They are composed of biocompatible materials, and with the safety and reliability of medical devices under a quality system of maximum guarantees.
- They offer high protection to the patient, by meeting the sanitary requirements applicable to products for clinical use.
> Scientific evidence
- Technology endorsed by more than 200 indexed scientific publications
Formulation
Endoret® PRGF® is a closed system, with the necessary equipment and unitary and disposable kits certified for such use that allows a rapid preparation of plasma under sterile conditions and its immediate application.
Why use Endoret instead of other PRPs?
The Endoret system provides many advantages:
> Autologous and rich in Growth Factors
- No adverse effects or incompatibility risks
- It promotes homeostasis
- Stimulates cell proliferation and migration
- It stimulates the endogenous secretion of proteins from the extracellular matrix
> Optimal concentration of Growth Factors
- Platelet concentration compared to baseline between 2 and 3 times
- Balance between growth factors:
- Platelet-based (released by platelets)
- Plasma-based (present free in plasma)
> Free from leukocytes and inflammatory proteins
- Reduces inflammation, pain, and tissue fibrosis
- Preserves the integrity of the fibrin matrix over time
> Controlled activation
- Promotes the release of growth factors from platelet
- Induces polymerisation of the fibrin matrix
> Dual effect and bioavailability
- Endoret PRGF works on tissues with its double action:
- Immediate, due to the effect of the growth factors at the time of application
- Prolonged over time, thanks to the fibrin matrix that acts as a reservoir for sustained release
> Versatility
- Makes it possible to prepare specific formulations adapted to each tissue and clinical need
> Security and compliance guarantees
- All necessary medical equipment and devices for Endoret closed system technology:
- They have CE marking for obtaining Plasma Rich in Growth Factors (PRGF)
- They comply with the most exhaustive quality controls in compliance with the current regulations (control of endotoxins and sterility, etc…)
- They are composed of biocompatible materials, and with the safety and reliability of medical devices under a quality system of maximum guarantees.
- They offer high protection to the patient, by meeting the sanitary requirements applicable to products for clinical use.
> Scientific evidence
- Technology endorsed by more than 200 indexed scientific publications
PRGF Autologous Eye Drops
- Fibrin-free autologous plasma formulation
- Quick and easy to prepare, without dilutions
- Accelerates tissue regeneration due to its high concentration of growth factors that promote cell proliferation and migration
- High anti-fibrotic potential that favors corneal transparency and protects against corneal scars and leukoma
- Daily treatment without the need to store in the refrigerator that can be used anywhere and at any time
Immunosafe Autologous PRGF Eye Drops
- Autologous eye drops with ImmuneSafe treatment helps patients with conditions in which the immune system plays a significant role such as Sjögren’s syndrome and graft-versus-host disease.
What’s the difference between the closed and the open technique?
In the closed technique, the method for obtaining PRP is by means of disposable, single-use kits; the instructions given by the manufacturer of each system must be followed without it being necessary to obtain a certificate of adequacy from the facilities. In the open technique, the method for obtaining PRP should be evaluated and authorised by an inspection by the competent health regulation to verify the suitability of the facilities and the production activities.
Endoret® (PRGF®) falls under the category that uses disposable kits, that is, the “closed technique”. The kit contains all of the elements required for obtaining plasma rich in growth factors formulations, without needing to use external elements.
References – Click here for the Literature Review
Anitua E, de la Sen-Corcuera B, Orive G, Sánchez-Ávila RM, Heredia P, Muruzabal F, Merayo-Lloves J. Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus. Expert Opin Biol Ther. 2021 Jul 19:1-15. doi: 10.1080/14712598.2021.1945030.
Anitua E, de la Fuente M, Muruzabal F, Riestra A, Merayo-Lloves J, Orive G. Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. Exp Eye Res. 2015 Jun;135:118-26. doi: 10.1016/j.exer.2015.02.016.
Freire V, Andollo N, Etxebarria J, Hernáez-Moya R, Durán JA, Morales MC. Corneal wound healing promoted by 3 blood derivatives: an in vitro and in vivo comparative study. Cornea. 2014 Jun;33(6):614-20. doi: 10.1097/ICO.0000000000000109.
Merayo-Lloves J, Sanchez-Avila RM, Riestra AC, et al. Safety and Efficacy of Autologous Plasma Rich in Growth Factors Eye Drops for the Treatment of Evaporative Dry Eye. Ophthalmic Res. 2016;56(2):68-73. doi:10.1159/000444496
Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, et al. Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops. Int Ophthalmol. 2018;38(3):1193-1204. doi:10.1007/s10792-017-0582-7